Compare EQT & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQT | TEVA |
|---|---|---|
| Founded | 1925 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | EQT | TEVA |
|---|---|---|
| Price | $53.78 | $31.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $64.58 | $32.11 |
| AVG Volume (30 Days) | 8.7M | ★ 10.3M |
| Earning Date | 10-21-2025 | 01-28-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 334.04 | N/A |
| EPS | ★ 2.91 | 0.62 |
| Revenue | $7,708,868,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $66.28 | $4.62 |
| Revenue Next Year | $15.91 | $0.34 |
| P/E Ratio | ★ $18.41 | $50.57 |
| Revenue Growth | ★ 66.75 | 0.02 |
| 52 Week Low | $42.85 | $12.47 |
| 52 Week High | $62.23 | $31.28 |
| Indicator | EQT | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 83.76 |
| Support Level | $52.74 | $28.00 |
| Resistance Level | $55.41 | $30.44 |
| Average True Range (ATR) | 1.72 | 0.69 |
| MACD | -0.64 | 0.01 |
| Stochastic Oscillator | 8.06 | 98.09 |
EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.